Inactive Instrument

Highlights Cerulean Pharma Inc Nasdaq

Equities

US15708Q1058

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	Apr. 23	CI
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31	CI
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	Dec. 20	CI
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	Dec. 07	MT
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1	Dec. 07	CI
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Dec. 04	CI
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs	Nov. 20	CI
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 09	CI
Daré Bioscience, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-10	CI
Dare Bioscience Awarded $385,000 Grant to Develop Therapy for Idiopathic Preterm Birth	23-07-31	MT
Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth	23-07-31	CI
Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women	23-07-11	CI
DarÃ© Bioscience, Inc. Provides Update on Activities to Support Commercial Launch of XACIATO	23-07-05	CI
DarÃ© Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women	23-06-21	CI
Dare Bioscience, Inc. Announces Positive Topline Data from the Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder	23-06-05	CI
Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1	23-02-22	CI
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause	23-01-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cerulean Pharma Inc Nasdaq

Equities

US15708Q1058

Highlights

Filters